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Abstract
Angiotensin II type 1 receptor (AGTR1) has been reported to play a fibrogenic role in non-alcoholic fatty liver disease
(NAFLD). In this study, five variants of the AGTR1 gene (rs3772622, rs3772627, rs3772630, rs3772633, and rs2276736) were
examined for their association with susceptibility to NAFLD. Subjects made up of 144 biopsy-proven NAFLD patients and
198 controls were genotyped using TaqMan assays. The liver biopsy specimens were histologically graded and scored
according to the method of Brunt. Single locus analysis in pooled subjects revealed no association between each of the five
variants with susceptibility to NAFLD. In the Indian ethnic group, the rs2276736, rs3772630 and rs3772627 appear to be
protective against NAFLD (p= 0.010, p= 0.016 and p= 0.026, respectively). Haplotype ACGCA is shown to be protective
against NAFLD for the Indian ethnic subgroup (p= 0.03). Gene-gene interaction between the AGTR1 gene and the patatin-
like phospholipase domain-containing 3 (PNPLA3) gene, which we previously reported as associated with NAFLD in this
sample, showed a strong interaction between AGTR1 (rs3772627), AGTRI (rs3772630) and PNPLA3 (rs738409) polymorphisms
on NAFLD susceptibility (p= 0.007). Further analysis of the NAFLD patients revealed that the G allele of the AGTR1 rs3772622
is associated with increased fibrosis score (p= 0.003). This is the first study that replicates an association between AGTR1
polymorphism and NAFLD, with further details in histological features of NAFLD. There is lack of evidence to suggest an
association between any of the five variants of the AGTR1 gene and NAFLD in the Malays and Chinese. In the Indians, the
rs2276736, rs3772630 and rs3772627 appear to protect against NAFLD. We report novel findings of an association between
the G allele of the rs3772622 with occurrence of fibrosis and of the gene-gene interaction between AGTR1gene and the
much-studied PNPLA3 gene.
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Introduction
The studies on non-alcoholic fatty liver disease (NAFLD) have
rapidly increased since the term non-alcoholic steatohepatitis was
first introduced by Ludwig et al [1]. NAFLD, defined as fatty
accumulation of the liver without significant alcohol intake, ranges
from simple steatosis to non-alcoholic steatohepatitis (NASH) and
cirrhosis [2]. The histological features of NAFLD include steatosis,
lobular inflammation, hepatocellular ballooning and fibrosis [3].
NAFLD is the hepatic manifestation of metabolic syndrome [4–8].
Although environmental factors, lifestyle and dietary intake
underlie susceptibility to NAFLD, genetic factors play a significant
upstream role [9–11].
The renin-angiotensin system acts on the hepatic stellate cells
(HSC) to promote hepatic fibrosis [12–13]. The AGTR1 gene has
been implicated with susceptibility to NAFLD [13–14]. To date,
there is only one study of AGTR1 polymorphism and its association
with the occurrence of NAFLD. The single nucleotide polymor-
phisms (SNPs) are located in the intron of AGTR1 on chromosome
3. In the study, five variants of AGTR1(rs3772622, rs3772627,
rs3772630, rs3772633, and rs2276736) were revealed to be
strongly associated with risk of NAFLD [15]. Furthermore, the
deletion of angiotensin II type 1 receptor in animals was associated
withdecreased hepatic steatosis. Thus, AGTR1 may be an
important regulator of steatosis in the liver [16].
The data on AGTR1 gene polymorphisms and its association
with NAFLD is currently limited to one study, therefore, we
investigated the association between five previously reported SNPs
of the AGTR1 gene with NAFLD susceptibility, in three major
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ethnic subgroups of the Malaysian population, namely the Malays,
Chinese and Indians. These three ethnic groups, which are
presumably of different genetic pools, provide a good setting to
study possible ethnic differences in susceptibility to NAFLD. We
further evaluated the association between the SNPs mentioned
and the histological features of NAFLD, namely steatosis, lobular
inflammation, hepatocellular ballooning and fibrosis. We previ-
ously reported in this same subjects, the association between
PNPLA3 with NAFLD and disease severity [17]. In this study, we
report new findings for the interaction between the AGTR1 gene
and the PNPLA3 gene on susceptibility to NAFLD.
Methods
Ethics Statement
Subjects provided written informed consent after a full
explanation of the research outline. The study protocol was
reviewed and approved by the Medical Ethics Committee of
University Malaya Medical Centre (UMMC).
Subjects
A case control study conducted at the UMMC recruited a total
of 144 cases and 198 controls. All cases were biopsy-proven
NAFLD patients based on increased echogenicity (compared to
renal cortex) on ultrasound with or without abnormal alanine
transferase (ALT). Ethnicity of the subjects were confirmed by
affirmations of absence of mixed marriages for at least three
generations.Exclusion criteria included alcohol consumption .
10g/day [18], hepatitis B or C infection, autoimmune hepatitis,
those who had been on drugs that are known to cause steatosis,
and Wilson’s disease. All the biopsy specimens were on an average
1.5 cm long and contained six portal tracts. The biopsy specimens
were graded according to the method of Brunt [19–20]. The
controls were genetically unrelated healthy subjects presenting
with body mass index (BMI) ,25 kg/m2, fasting plasma glucose
,110 mg/dL, normal lipid profile and normal liver enzymes.
NAFLD was excluded in the controls by ultrasonography
according to the absence of the following criteria; diffuse increase
in bright echoes in the liver parenchyma (exceeding that of renal
cortex and spleen) with impaired visualization of the peripheral
portal and hepatic vein borders, and/or loss of definition of the
diaphragm and poor delineation of the portal and hepatic radicles.
Clinical and laboratory assessments
Venous blood samples were taken for the determination of
haemoglobin A1c (HbA1c), total cholesterol, triglycerides, high-
density lipoprotein cholesterol (HDL), low-density lipoprotein
cholesterol (LDL), alanine transferase (ALT), aspartate amino-
transferase (AST), and gamma-glutamyl transpeptidase (GGT)
level in all subjects. The biochemical tests were analysed based on
standard clinical laboratory methods. Other relevant parameters
such as body mass index (BMI), waist circumference and blood
pressure weredetermined according to standard protocol.
Genotyping
Blood samples were collected in EDTA tubesandgenomic DNA
was prepared using the QiAamp DNA Mini Kit (Qiagen. Hilden,
German) according to user protocol. The AGTR1 SNPs were
genotyped using a predesigned TaqMan SNP genotyping assay
(Applied Biosystems, Foster City, CA, USA) as previously
described [17].
Statistical analyses
All values are presented as mean6standard deviation for
continuous data and as percentages for categorical data. For
normally distributed variables (age, BMI, waist circumference,
ALT, HDL cholesterol, LDL cholesterol, total cholesterol,
triglycerides, and systolic blood pressure), independentt-test was
performed to determine the associations between the different
grades of NAFLD. For variables that are not normally distributed
(HbA1c, AST, GGT, diastolic blood pressure, steatosis grade,
lobular inflammation, ballooning, and fibrosis), Mann-Whitney U
test was performed. Hardy-Weinburg equilibirum (HWE) was
checked for all the groups using a goodness-of fit x2 test with one
degree of freedom. A p value of less than 0.05 indicated a lack of
agreement with HWE.
Association of allele was performed using logistic regression.
Likelihood tests indicated a significant effect of ethnicity but no
significant effect of age and gender. In order to avoid false
discoveries due to population stratification, the association analysis
was performed for each marker (SNP/haplotype) separately for
each ethnic group. To come up with an overall estimate, the
estimates from the different ethnic groups were combined using
inverse variance weighting (IVW) technique, usually used for
combining estimates in meta-analysis. The calibration and fit of
the model were assessed using Hosmer Lemeshow goodness of fit
and receiver operating characteristic (ROC) curves. Kruskal-
Wallis test was performed for comparison of medians between
three groups.
To investigate the influence of gene-gene interaction on
NAFLD, Generalized Multifactor Dimensionality Reduction
(GMDR) method was employed [21]. All possible interactions
were tested using 10-fold cross validation with exhaustive search,
which considers all possible variable combinations. GMDR
provides a cross-validation consistency score which is a measure
of the degree of consistency with which the selected interaction is
identified as the best model among all possibilities considered. The
testing balanced accuracy generated is a measure of the degree to
which the interaction accurately predicts case-control status.
Testing accuracy is a measure of the strength of gene-gene
interaction with a power of 80% at an accuracy of 0.58–0.60,
given a sample of,500 [22]. In addition, logistic regression model
was performed to confirm the results of gene interaction analyses.
Ethnicity was used as covariate in the gene-gene interaction
analysis.
Univariate analysis of association of genotypes and histological
ordinal variables was assessed using the Jonckheere-Terpstra test.
Ordinal regression is perfomed for multivariate analysis of
histological ordinal variables. To correct for testing for multiple
histological parameters, the false discovery rate (FDR) was
calculated using Benjamini-Hochberg procedure[23]. Analyses
were performed using SPSS 16.0 (Chicago IL) with a two sided p,
0.05 considered to be statistically significant. Linkage disequilib-
rium and haplotype analyses for the five SNPs were performed
using Haploview 4.2 program. The odds ratio for the haploypes
was calculated using R software version 2.11.1.
We estimated that a sample size of 117 cases and 161 controls
would provide 80% power at a of 0.05 with the following
assumptions: the allele frequency range from 0.31-0.41, the
baseline risk for the Malaysian population was 0.17, and the
minimum detectable odds ratio was 2.0.
Results
Table 1 shows the demographic and clinical data of the NAFLD
case (n = 144) and the control (n = 198) groups. There were 59
AGTR1 Polymorphisms and NAFLD
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(41%) Malays, 54 (38%) Chinese and 31 (21%) Indians in the
NAFLD group. Out of the 198 controls, 80 (41%) were Malays, 54
(27%) Chinese and 64 (32%) Indians. The differences in the
parameters of BMI, HbA1c, LDL cholesterol, total cholesterol,
triglycerides, AST, ALT and GGT between the two groups reflect
the nature of the selection of the cases and controls.
Table 2 further describes the demographic and clinical data of
the NAFLD subjects grouped into simple steatosis (n = 33) and
NASH (n= 111). The BMI, HbA1c, waist circumference, triglyc-
erides, systolic, and diastolic blood pressure were significantly
higher in the NASH group (p,0.05) as compared to the simple
steatosis group.
Genotypes and allele frequencies of AGTR1
polymorphisms
The genotypes of each SNP were in Hardy-Weinberg equilib-
rium for both NAFLD cases and controls, for pooled subjects as
well as after stratification by ethnicity. The association tests
between NAFLD and control subjects are shown in Table 3. None
of the SNPs were associated with susceptibility to NAFLD.
However, after ethnic stratification, in the Indian ethnic subgroup,
the rs2276736, rs3772630 and rs3772627 were found to be
protective against NAFLD (OR 0.40, 95% CI 0.20–0.81,
p=0.010; OR 0.43, 95% CI 0.22–0.86, p=0.016; and OR 0.46,
95% CI 0.23–0.91, p=0.026, respectively). We showed the sample
power for the significant findings to be . 81%.
We then divided the NAFLD group into simple steatosis and
NASH but did not find any association between the five SNPs with
susceptibility to NASH in the pooled subjects (Table 3). Results by
ethnicity group show that in the Indian ethnic subgroup, the three
SNPs (rs2276736, rs3772630 and rs3772627) were also protective
against NASH (OR 0.42, 95% CI 0.21–0.86, p=0.017; OR 0.46,
95% CI 0.22–0.92, p=0.029; and OR 0.49, 95% CI 0.24–0.98,
p=0.045, respectively).
Gene-gene interaction analysis
The overall results, pooling all subjects, indicate a lack of
evidence for an association betweenAGTR1 gene and NAFLD,
which is in contrast with the positive findings by Yoneda et. al
[15]. Our previous study showed a strong association of PNPLA3
gene with the occurence of NAFLD [17], and we were therefore
curious to find out whether there is any gene-gene interaction
between PNPLA3 and AGTR1. The results with the two-locus and
three-locus models are shown in Table 4. The two-locus model has
the highest testing accuracy while the three-locus model has the
best cross-validation consistency. Investigation of the gene-gene
interaction on the occurence of NAFLD, identified a significant
effect of PNPLA3 and AGTR1 interaction (empirical p=0.007).
The best GMDR model suggested for the interaction was the
three-locus model. The significant interaction was confirmed by
logistic regression (permuted p=0.017).
Genotype association in additive model revealed that the risk
genotypes (AGTR1 rs3772627TT, AGTR1 rs3772630AA and
PNPLA3 rs738409GG) versus one risk factor (AGTR1
rs3772627TC, AGTR1 rs3772630AG and PNPLA3 rs738409CG)
versus the protective genotypes (AGTR1 rs3772627CC, AGTR1
rs3772630GG and PNPLA3 rs738409CC), conferred enhanced
risk for NAFLD (OR 2.23, 95% CI 1.16–4.31, p=0.017). Since
the protective effect was seen in the Indian ethnic subgroup, we
Table 1. Demographic and clinical data of the subjects.
Characteristics n (%) or Mean±SD
Control (n=198) NAFLD (n=144) p value
Gender 0.084
Males 85 (43) 77 (53)
Females 113 (57) 67 (47)
Ethnicity
Malays 80 (41) 59 (41)
Chinese 54 (27) 54 (38)
Indians 64 (32) 31 (21)
Age (years) 53.1611.5 51.2612.0 0.136
BMI (kg/m2) 22.762.6 28.764.4 ,0.0001
HbA1c (%) 5.760.8 6.661.7 ,0.0001
HDL cholesterol (mg/dl) 49.5612.9 48.5612.7 0.31
LDL cholesterol (mg/dl) 89.5622.4 117.1640.0 ,0.0001
Total cholesterol (mg/dl) 176.4626.9 196.7644.0 ,0.0001
Triglycerides (mg/dl) 118.4632.3 155.0662.7 ,0.0001
AST (IU/L) 21.869.5 42.9625.4 ,0.0001
ALT (IU/L) 36.0616.6 83.0648.5 ,0.0001
GGT (IU/L) 44.0625.4 111.66115.5 ,0.0001
Data are expressed as mean6SD for continuous data and as percentage for
categorical data.
ALT alanine transferase, AST aspartate aminotransferase, BMI body mass index,
GGT gamma glutamyl transpeptidase, HbA1c haemoglobin A1c, HDL high-density
lipoprotein, LDL low-density lipoprotein, NAFLD non-alcoholic fatty liver disease.
p values obtained using Mann-Whitney U test.
doi:10.1371/journal.pone.0058538.t001
Table 2. Demographic and clinical data of the NAFLD
patients.
Characteristics n (%) or Mean±SD
Simple
steatosis
(n =33)
NASH
(n=111) p value
Gender, n (%) 0.461
Males 20 (61) 57 (51)
Females 13 (39) 54 (49)
Age (years) 50.7611.8 51.2612.1 0.82
BMI (kg/m2) 26.763.9 29.264.4 0.003
HbA1c (%)* 6.161.3 6.761.7 0.021
Waist circumference (cm) 89.2611.2 95.2610.4 0.005
HDL cholesterol (mg/dl) 50.2615.1 48.0611.9 0.391
LDL cholesterol (mg/dl) 114.7642.8 117.8639.3 0.698
Total cholesterol (mg/dl) 191.6644.9 198.2643.8 0.448
Triglycerides (mg/dl) 124.6642.0 164.1665.1 0.001
AST (IU/L)* 37.6621.3 44.5626.3 0.139
ALT (IU/L) 71.9650.0 86.4647.8 0.134
GGT (IU/L)* 99.46106.6 115.36118.2 0.132
Systolic blood pressure (mmHg) 125.2613.0 134.2614.1 0.001
Diastolic blood pressure (mmHg)* 78.269.1 83.869.7 0.003
ALT alanine transferase, AST aspartate aminotransferase, BMI body mass index,
GGT gamma glutamyl transpeptidase, HbA1c haemoglobin A1c, HDL high-
density lipoprotein, LDL low-density lipoprotein, NAFLD non-alcoholic fatty liver
disease, NASH non-alcoholic steatohepatitis
*P values obtained using Mann-Whitney U test, all other comparisons used
independent t test
doi:10.1371/journal.pone.0058538.t002
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additionally tested the association specifically in this group. The
risk for NAFLD in this group was dramatically enhanced (OR
12.41, 95% CI 1.61–55.42), p=0.016) following genotypes
combinations. We showed that the gene-gene interaction with
an effect size of 4.5 would provide a power of . 79%. We further
evaluated the association of AGTR1 SNPs with NAFLD following
stratification by PNPLA3 genotypes. The results indicated the
absence of significant association (data not shown).
AGTR1 polymorphisms and liver histology
Of the five SNPs, rs3772622 was the only SNP to show
association with liver histology in the NAFLD patients (Table 5).
The GG genotype of this SNP is significantly associated with
increased in fibrosis (p=0.009) (Fig. 1). It has to be noted that the
rs3772622 is not among the SNPs that have been found to be
protective. To investigate whether the G allele of the rs3772622 is
associated with risk of fibrosis, we performed univariate and
multivariate tests. The G allele of this SNP was shown to be
associated with presence of fibrosis (p=0.003). Subjects with the G
allele has a propensity of 2.18 times to develop fibrosis score $ 2.
The association remains significant (p=0.003) after adjustment of
other histological attributes (Table 5). We also investigated the
remaining SNPs and their association with histological features of
NAFLD, however none of them showed a significant association
(data not shown).
Linkage disequilibrium and haplotype analysis of AGTR1
SNPs
Linkage disequilibrium (LD) analysis revealed a strong LD
between the five SNPs in overall subjects and after ethnic
stratification except between rs3772633 and rs3772622. Variants
rs2276736 and rs3772630 are in complete LD in the Chinese and
Malays, however variants rs2276736 and rs3772627 are in
complete LD in the Chinese only (Table 6).
Four haplotypes with frequencies of above 5% are presented in
Table 7. In pooled subjects, haplotypes ATATG, GCGCA and
ATATA are more frequent than the others (35.1%, 21.8% and
20.9%, respectively). Similar results are observed in the Malays
(37.8%, 22.7% and 23.2%, respectively). Meanwhile in the
Chinese, the most frequent haplotypes are ATATG (34.8%) and
GCGCA (25.9%). The Indians on the other hand has high
frequency of haplotypes ATATG (31.4%), ATATA (22.3%) and
ACGCA (24.7%). Each of the following haplotypes, ATATG,
GCGCA, ATATA and ACGCA is significantly different among
the ethnic groups (p, 0.0001, for each haplotype respectively).
Table 3. Association tests of AGTR1 SNPs and NAFLD.
NAFLD spectrum All ethnicities* Malay Chinese Indian
MAF OR (CI) p MAF OR (CI) p MAF OR (CI) p MAF OR (CI) p
rs2276736(T.C)**
Control as reference 0.42 1.00 0.35 1.00 0.43 1.00 0.49 1.00
NAFLD 0.38 0.82 (0.48–1.37) 0.445 0.36 1.03 (0.61–1.15) 0.917 0.44 1.08 (0.62–1.88) 0.778 0.27 0.40 (0.20–0.81) 0.010
Simple steatosis 0.41 0.99 (0.55–1.79) 0.968 0.33 0.93 (0.37–2.31) 0.873 0.5 1.35 (0.62–2.93) 0.450 0.25 0.35 (0.07–1.81) 0.209
NASH 0.36 0.78 (0.46–1.34) 0.366 0.36 1.05 (0.61–1.81) 0.848 0.42 0.97 (0.53–1.78) 0.925 0.3 0.42 (0.21–0.86) 0.017
rs3772622 (A.G)
Control as reference 0.38 1.00 0.38 1.00 0.41 1.00 0.34 1.00
NAFLD 0.42 1.17 (0.87–1.59) 0.301 0.45 1.30 (0.81–2.07) 0.275 0.4 0.97 (0.58–1.61) 0.896 0.4 1.32 (0.69–2.53) 0.409
Simple steatosis 0.38 0.97 (0.57–1.65) 0.912 0.33 0.83 (0.35–1.97) 0.666 0.38 0.91 (0.43–1.94) 0.804 0.5 1.96 (0.45–8.55) 0.371
NASH 0.43 1.22 (0.88–1.69) 0.226 0.48 1.46 (0.88–2.42) 0.142 0.41 0.99 (0.58–1.71) 0.981 0.39 1.24 (0.62–2.46) 0.546
rs3772633 (A.G)
Control as reference 0.23 1.00 0.23 1.00 0.3 1.00 0.19 1.00
NAFLD 0.28 1.21 (0.86–1.70) 0.282 0.28 1.28 (0.75–2.18) 0.370 0.34 1.23 (0.70–2.16) 0.475 0.19 1.04 (0.49–2.21) 0.922
Simple steatosis 0.24 0.99 (0.53–1.84) 0.965 0.17 0.66 (0.21–2.08) 0.473 0.35 1.27 (0.58–2.80) 0.550 0.12 0.61 (0.07–5.34) 0.656
NASH 0.3 1.31 (0.91–1.88) 0.150 0.31 1.45 (0.83–2.55) 0.190 0.34 1.20 (0.65–2.23) 0.564 0.22 1.23 (0.57–2.66) 0.597
*Results based on combining results across ethnicities
**Only results of rs2276736 presented due to very high LD of rs2276736, rs3772630, rs3772627. The results for rs3772630 and rs3772627 are similar to rs2276736 (Table
S1)
CI confident interval, MAF minor allele frequency, NAFLD non-alcoholic fatty liver disease, NASH non-alcoholic steatohepatitis, OR odds ratio
doi:10.1371/journal.pone.0058538.t003
Table 4. Best fitted gene-gene interaction model.
Locus
number Model
Cross-validation
consistency Testing accuracy (%) pvalue*
2 AGTR1 (rs2276736), PNPLA3 (rs738409) 8/10 63.68 0.038
3 AGTR1 (rs3772627), AGTRI (rs3772630), PNPLA3 (rs738409) 9/10 62.88 0.007
*P values based on 1000 permutations. Analysis of GMDR with adjustment of ethnicity
doi:10.1371/journal.pone.0058538.t004
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Haplotype analysis revealed that haplotype ACGCA was protec-
tive against NAFLD in the Indians (OR 0.42, 95% CI 0.15-0.95,
p=0.03). Since rs2276736, rs3772630 and rs3772627 are
presented in similar structure and some were in complete LD,
we further analysed the haplotype among the three SNPs. We
found that the Indians presenting with the CGC haplotype were
protected (OR 0.41, 95% CI 0.21–0.84, p=0.015) against
NAFLD (data not shown).
Discussion
Angiotensin II appears to have an important role in the
progression to non-alcoholic steatohepatitis (NASH) [13–14].
Angiotensin II acts on angiotensin II type 1 receptor to activate
hepatic stellate cells (HSCs). The activated HSCs will express the
transforming growth factor-b 1 (TGF-b 1), a profibrogenic
cytokine, as a counter response to liver injury [12–13]. The
preventive role of AGTR1 blocker in the progression to NASH was
succesfully observed in the animaland human studies [24–27]. The
deletion of angiotensin II type 1 receptor in animal studies has
been shown to reduce hepatic steatosis suggesting AGTR1 is an
important regulator of hepatic steatosis [16].
In the present study, our data indicated that the five previously
reported SNPs of the angiotensin II type I receptor (AGTR1) gene
(rs3772622, rs3772627, rs3772630, rs3772633, and rs2276736)
were not associated with susceptibility to non-alcoholic fatty liver
disease (NAFLD) and non-alcoholic steatohepatitis (NASH). This
is in contrast with the Japanese study which showed that these
AGTR1 polymorphisms were significantly associated with the
occurence of NAFLD and NASH [15].
Among the SNPs studied, rs2276736, rs3772630 and rs3772627
were found to be protective against NAFLD and NASH in the
Indian ethnic subgroup. Interestingly, these three SNPs share the
same linkage disequilibrium structure. We revealed that haplotype
ACGCA is protective against NAFLD in the Indians. The study by
Yoneda et al reported that the protective haplotype in the
Japanese was ATATG [15]. The discrepancy in the findings may
be explained by ethnic differences between the populations
studied. The three major ethnic subgroups in Malaysia, namely
the Malay, Chinese and Indian are of the south Asian origin with
the Chinese are of the Hans descendant of Southern China [28],
Indians from Southern India [29], whereas the Malays are the
indigenous ethnic group. There is a supportive evidence that the
Japanese are from the north Asian (Northern China and Korea)
origin but not the south Asian (Southern China and Southeast
Asia) based on the classical marker polymorphisms, Y chormo-
some and mitochondrial DNA [30–31]. The difference in the
association studies between the two population probably reflects
the difference in the genetic pools of the Malaysian and the
Japanese.
The results from our study indicated that there was no
difference in levels of liver enzymes between patients with simple
steatosis and those with NASH. This is in agreement with the
results from Sorrentino et al [32] and Mofrad et al [33], but is in
contrast with the findings of several other studies which showed
differences in levels between the two groups [34–37]. The
differences in these findings is probably due to the differences in
the recruitment of subjects for the various studies, in which
inclusion criteria ranges from morbid obese NAFLD to adults with
NAFLD. Furthermore, we observed a significantly higher triglyc-
erides levels in patients with NASH compared to those with simple
steatosis. Triglyceride storage in hepatocytesmarks the intensity of
exposure to potentially toxic fatty acids. As NAFLD progresses,
Figure 1. Mean fibrosis score among the genotypes of
rs3772622. p value calculated from comparison between three
groups using Kruskal-Wallis test.
doi:10.1371/journal.pone.0058538.g001
Table 5. Association of G allele of rs3772622 with histological features in NAFLD patients.
Histology
Univariate
pvaluea
multivariate pvalueb
(FDR qvalueg) OR (95% CI)
Steatosis
.33% (n = 85) vs. ,33% (n = 59)
0. 589 0.546 (0.728) 0.98 (0.61–1.56)c
Lobular inflammation
$2 foci (n = 51) vs. ,2 foci (n = 93)
0. 953 0.251 (0.502) 0.89 (0.55–1.45)d
Hepatocellular ballooning
$1 (n = 131) vs. ,1 (n = 13)
0. 395 0.744 (0.744) 2.08 (0.84–5.14)e
Fibrosis
$2 (n = 76) vs. ,2 (n = 68)
0. 003 0.003 (0.012) 2.18 (1.32–3.60)f
OR odds ratio, CI confident interval
aJonckheere-Terpstra test
bOrdinal regression
c, d, e, fMultivariate logistic regression
gFalse discovery rate, q,0.05 is significant
doi:10.1371/journal.pone.0058538.t005
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excess free fatty acids are compensated with increase in
triglycerides production [38].
Analysis of interaction between PNPLA3 and AGTR1 gene,
revealed a strong interaction between AGTR1 (rs3772627), AGTRI
(rs3772630) and PNPLA3 (rs738409) SNPs on NAFLD suscepti-
bility. Compared to the Malays and Chinese, the Indians
presented with the greatest susceptibilty to NAFLD in the PNPLA3
study [17]. Thus the PNPLA3can possibly mask the effect of
AGTR1 on NAFLD among the Indians. Although both genes
encode different products (PNPLA3 encodes adiponutrin while
AGTR1 encodes angiotensin II type 1 receptor), the strong
interaction observed suggested a possible interaction as both genes
are involved in lipid accumulation. The action of angiotensin II on
angiotensin II type 1 receptor (AGTR1) promotes lipid accumu-
lation in the liver whilelack of AGTR1 reduces hepatic triglycerides
[16]. Adiponutrin (PNPLA3) on the other hand is highly
upregulated in response to feeding and downregulated in fasting
state, displaying its role in lipid storage in the liver [39]. Of note,
AGTR1 and PNPLA3 are correlatively upregulated in a state of
excess lipid.
We further showed that the SNP rs3772622 was associated with
occurence of fibrosis but not with the other histological parameters
of NAFLD. The G allele of this SNP is associated with increased
fibrosis score. The Japanese also found that SNP rs3772622 was
associated with the presence of fibrosis [15], but in contrast to our
findings, the G allele was found to be associated with decreased
fibrosis score. The difference is probably explained by a higher
minor allele frequency in our population than that of the Japanese.
A greater systolic blood pressure mean value (136.00 mmHg)
observed in the GG genotype compared to the AA genotype
(128.65 mmHg) of the SNP rs3772633 could also contribute to the
discrepancy. Data of the previous report showed that hypertensive
patients have significantly higher fibrosis score than that of non-
hypertensive [40]. The strong linkage disequilibrium observed
between the five SNPs in the overall subjects and even after ethnic
stratification indicates a potential tagSNP selection based on the
pairwise LD. This approach will be useful in future in order to
minimize the genotyping cost yet presenting the information that
could reflect the role of the other relevant SNPs within the gene.
This present study has several limitations and strengths. Studies
on NAFLD spectrum have been limited since this requires valid
ascertainment and scoring of the different NAFLD stages, for
which liver biopsy is the gold standard in providing such accurate
diagnosis. Such biopsies are limited to situations when there is a
definite clinical indication for the biopsy, and this reflects the
relatively small sample size in our study. Unlike the diagnosis of
NASH, diagnosis of fatty liver can be made based on clinical,
radiological and laboratory findings, which therefore makes it
slightly easier to carry out studies on NAFLD. Ethics consideration
does not allow for biopsy in control subjects, thus no biopsies were
performed in controls. In order to reduce likelihood of misclas-
sifying the controls, a strict criteria are required. These criteria
Table 7. Haplotype frequencies of AGTR1 SNPs.
Haplotype Ethnicity
Chinese (n =108) Indian (n =95) Malay (n=139) Total (n = 342)
Case
(%)
Ctrl
(%) p ORa(95% CI)
Case
(%)
Ctrl
(%) p ORa (95% CI)
Case
(%)
Ctrl
(%) p ORa (95% CI)
Case
(%)
Ctrl
(%) pc ORa (95% CI)
ATATG 33 37 0.60 Referent 33 31 0.75 Referent 43 34 0.15 Referent 37 34 0.37 Referent
GCGCA 26 26 0.99 1.07 (0.54–2.10) 12 18 0.28 0.59 (0.20–1.68) 24 22 0.59 0.74 (0.38–1.44) 22 22 0.40 0.83 (0.54–1.28)
ATATA 16 18 0.67 1.02 (0.45–2.32) 31 18 0.05 1.62 (0.59–3.28) 18 27 0.09 0.54 (0.29–1.03) 20 22 0.62 0.86 (0.48–1.54)
ACGCA 15 14 0.84 1.26 (0.53–2.96) 15 29 0.03 0.42 (0.15–0.95) 8 12 0.34 0.53 (0.22–1.28) 13 18 0.23 0.66 (0.34–1.29)
Othersb 10 5 — — 9 4 — — 7 5 — — 8 4 — —
Total 100 100 — — 100 100 — — 100 100 — — 100 100 — —
CI confidence interval, Ctrl control, OR odds ratio, aOR estimated odds ratio by R, bHaplotypes with total frequencies below 5% in all subjects, cP values based on
combining results across ethnicities
doi:10.1371/journal.pone.0058538.t007
Table 6. Linkage disequilibrium coefficient among five SNPs
of AGTR1 gene.
SNP ID D9 Chinese
rs2276736 rs3772630 rs3772627 rs3772622
rs3772633 0.82 0.81 0.82 0.68
rs2276736 1.00 1.00 0.84
rs3772630 0.96 0.78
rs3772627 0.82
SNP ID D9 Indian
rs2276736 rs3772630 rs3772627 rs3772622
rs3772633 0.81 0.80 0.87 0.52
rs2276736 0.96 0.98 0.91
rs3772630 0.98 0.86
rs3772627 0.85
SNP ID D9 Malay
rs2276736 rs3772630 rs3772627 rs3772622
rs3772633 0.90 0.90 0.90 0.89
rs2276736 1.00 0.98 0.86
rs3772630 0.95 0.87
rs3772627 0.81
SNP ID D9 All Ethnicities
rs2276736 rs3772630 rs3772627 rs3772622
rs3772633 0.85 0.85 0.86 0.73
rs2276736 0.99 0.98 0.86
rs3772630 0.95 0.83
rs3772627 0.85
D9 linkage disequilibrium coefficient, SNP single nucleotide polymorphism
doi:10.1371/journal.pone.0058538.t006
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includes normal BMI, fasting plasma glucose, lipid profile and
liver enzymes. The difference in the distribution of these
parameters between the two extremes of the NAFLD disease
spectrum, provides confidence in the selection process of NAFLD
cases and controls. Mild steatosis among the controls cannot
however be ruled out and this may result in a bias towards the null.
The resulting association between AGTR1 gene and NAFLD was
smaller than hypothesized (OR less than 2.0) and would have
resulted in a loss of power for the relevant analysis. The small
sample size after stratification into simple steatosis and NASH is
another limitation for this study. A major strength of this study was
the ability to compare the association between AGTR1 polymor-
phisms and NAFLD among three major ethnic groups in Asia.
This study suggest that the rs2276736, rs3772630 and rs3772627
are protective against NAFLD among the Indians. This study is
also the first to report the interaction of gene between the AGTR1
and the commonly reported PNPLA3 gene on NAFLD suscepti-
bility.
In conclusion, the present study suggests that the AGTR1
variants rs2276736, rs3772630 and rs3772627 are protective
against NAFLD among the Indians. The G allele of rs3772622 is
significantly associated with presence of fibrosis. Among the
Malays and Chinese, we failed to find any significant association
between the five SNPs (rs3772622, rs3772627, rs3772630,
rs3772633, and rs2276736) of AGTR1 gene and susceptibility to
NAFLD. We report novel finding for the gene-gene interaction
between AGTR1 and the much-studied PNPLA3 genes. A larger
sample size and more ethnically diverse samples are needed to
replicate these findings.
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